MedTrace Logo

Candesartan Versus Propranolol for Migraine Prevention

NCT00884663 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2013-12-24

No results posted yet for this study

Summary

The main aim of the present study is to compare candesartan with propranolol for migraine prophylaxis.

Conditions

  • Migraine Without Aura
  • Migraine With Aura
  • Chronic Migraine

Interventions

DRUG

Candesartan

Candesartan cilexitil tablets, 16 mg once daily

DRUG

propranolol

Propranolol hydrochloride capsules 160 mg once daily, slow release formulation

DRUG

placebo

placebo tablets and capsules

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • St. Olavs Hospital

    collaborator OTHER

  • Kragerø Tablettproduksjon as, Norway

    collaborator UNKNOWN

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Lars J Stovner, Ph.D. · Norwegian National Headache Centre, St. Olavs Hospital

  • Lars J Stovner, Ph.D. · Norwegian National Headache Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00884663 on ClinicalTrials.gov